BAYER AG

Finerenone reduced heart failure events and cardiovascular death in HF patients with mildly reduced or preserved ejection fraction. The trial, led by Brigham and Women's Hospital and funded by Bayer, showed fewer HF events and cardiovascular deaths in the finerenone group compared to placebo, with higher rates of hyperkalemia. Results were presented at the European Society of Cardiology Congress 2024 and published in the New England Journal of Medicine.

JFK, PL, CCW, TYW, XZ, PMW, SL, LB, ZH, SF, KWC, KR, and SS have various consulting roles, advisory board memberships, or research support from numerous pharmaceutical and medical technology companies.

Elinzanetant, a dual NK-1 and 3 receptor antagonist, showed efficacy and safety in Phase III OASIS 1 and 2 studies for treating moderate to severe VMS in menopause, reducing VMS frequency and severity, and improving sleep disturbances and quality of life.

Bayer starts Phase II ALPINE-1 study of BAY3283142, an sGC activator for chronic kidney disease, aiming to provide a new treatment option for cardiovascular diseases.

Elinzanetant, a dual NK-1 and 3 receptor antagonist, showed efficacy and safety in treating moderate to severe VMS associated with menopause in Phase III OASIS 1 and 2 studies. It significantly reduced VMS frequency and severity, improved sleep disturbances, and menopause-related quality of life, with a favorable safety profile.

Bayer submitted a New Drug Application to the FDA for elinzanetant, a non-hormonal treatment for menopause-related hot flashes, based on positive Phase III OASIS studies. Elinzanetant significantly reduces VMS frequency and severity, improving quality of life with a favorable safety profile.

Bayer submitted a New Drug Application (NDA) to the U.S. FDA for elinzanetant, an investigational compound for treating moderate to severe vasomotor symptoms (VMS) associated with menopause, based on positive results from Phase III OASIS 1, 2, and 3 studies. Elinzanetant, a non-hormonal option, significantly reduced VMS frequency and severity with a favorable safety profile, marking a milestone in addressing women's health needs globally.

The biosimilars market is expanding, with the global market projected to hit $43.8 billion by 2024 and exceed $100 billion in a decade. Recent FDA and EMA approvals include biosimilars for Johnson & Johnson’s Stelara and Bayer’s Eylea, following patent expirations. Notable approvals include Pyzchiva, Ahzantive, Yesafily, Opuviz, Hercessi, Selarsdi, Wyost, Jubbonti, Simlandi, and Uzpruvo, targeting various conditions and expected to launch by 2025.

The precision medicine market, valued at $73.11 billion in 2023, is projected to grow to $118.08 billion by 2028, driven by rising cancer prevalence and strategic collaborations. It segments by technology, application, and end-use, with major players including Roche, Pfizer, and Novartis.